A dose-response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m)

High Altitude Medicine and Biology

Volumn 5, Issue 1, 2004, Pages 33-39

  Carlsten, Chris ^a   Swenson, Erik R ^a   Ruoss, Stephen ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Altitude sickness; Carbonic anhydrase inhibitor; High altitude; Lake louise score; Randomized placebo controlled trial

Indexed keywords

ACETAZOLAMIDE; ASCORBIC ACID; PLACEBO;

ACUTE DISEASE; ALTITUDE; ALTITUDE DISEASE; ARTICLE; BOLIVIA; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXERCISE; HUMAN; LASSITUDE; LEISURE; NAUSEA; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEA LEVEL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TOURISM;

ACETAZOLAMIDE; ACUTE DISEASE; ADULT; ALTITUDE SICKNESS; BOLIVIA; CARBONIC ANHYDRASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PULMONARY EDEMA; QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 1842588604     PISSN: 15270297     EISSN: None     Source Type: Journal    
DOI: 10.1089/152702904322963672     Document Type: Article

References (26)

1. Basnyat B., Gertsch J.H., Johnson E.H., Castro-Marin F., Inoue Y., and Yeh C. (2003). Efficacy of low dose acetazolamide (125 mg bid) for the prophylaxis of acute mountain sickness: A prospective, double-blind, randomized, palcebo-controlled trail. High Alt. Med. Biol. 4:45-52.
2. Bernstein R.E. (1958). Factors conditioning electrolyte balance and renal function during diuresis produced by carbonic anhydrase inhibition in normal subjects. S. Afr. J. Med. Sci. 23:167-185.
3. Coote J. (1991). Pharmacological control of altitude sickness. Trends Pharmacol. Sci. 12:450-455.
4. Dumont L., Mardisoff C., and Tramer M. (2000). Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systemic review. Brit. Med. J. 321:267-272.
5. Ellsworth A.J., Larson E.B., and Strickland D. (1987). A randomized trial of dexamethasone and acetazolamide for acute mountain sickness prophylaxis. Am. J. Med. 83:1024-1030.
6. Ellsworth A.J., Meyer E.F., and Larson E.B. (1991). Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Ranier. West. J. Med. 154:289-293.
7. Galdston M. (1955). Respiratory and renal effects of a carbonic anhydrase inhibitor (Diamox) on acid-base balance in normal man and in patients with respiratory acidosis. Am. J. Med. 19:516-532.
8. Gray G.W., Frayser R., Houston C.S., and Rennie I.D. (1971). Control of acute mountain sickness. Aerospace Med. 42:81-84.
9. Hackett P.H., and Rennie I.D. (1976). The incidence, importance and prophylaxis of acute moutain sickness. Lancet 27 Nov:1149-1154.
10. Hackett P.H. and Rennie I.D. (1979). Rales, peripheral edema, retinal hemorrage and acute mountain sickness. Am. J. Med. 67:214-218.
11. Hackett P.H., and Rennie I.D. (1983). Acute mountain sickness. Semin. Respir. Med. 5:132-139.
12. Hackett P.H., and Roach R.C. (1987). Medical therapy of altitude illness. Ann. Emerg. Med. 16:980-986.
13. Heath D., and Williams D.R. (1995). In: High Altitude Medicine and Pathology, Oxford Press, Oxford, p. 4.
14. Honigman B., Theis M.K., Koziel-McLain J., Roach R., Yip R., Houston C., Moore L.G., and Pearce P. (1993). Acute mountain sickness in a general tourist population at moderate altitudes. Ann. Int. Med. 118:587-592.
15. Larson E.B., Schoene R.B., Roach R., Hornbein T.F. (1982). Acute mountain sickness and acetazolamide. J. Am. Med. Assoc. 248:328-332.
16. Montgomery A.B., Mills J., and Luce J.M. (1989). Incidence of acute mountain sickness at intermediate altitude. J. Am. Med. Assoc. 261:732-734.
17. Roach R.C., Bartsch P., Oelz O., and. Hackett P.H. (1993). Lake Louise AMS Scoring Consensus Committee. The Lake Louise acute mountain sickness scoring system. In: Hypoxia and Molecular Medicine. J.R. Sutton, G. Coates, and C.S. Houston, eds. Queen City Press, Burlington, VT, pp. 272-274.
18. Roach R.C., Maes D., Sandoval D., Robergs R.A., Icenogle M., Hinghofer H., Lium D., and Loeppky J.A. (2000). Exercise exacerbates acute mountain sickness at simulated high altitude. J. Appl. Physiol. 88:581-585.
19. Roeggla G., Roeggla M., Podolsky A., Wagner A., and Laggner A.N. (1996). How can acute mountain sickness be quantified at moderate altitude? J. R. Soc. Med. 89:141-143.
20. Singh I., Khanna P.K., Srisvsatana M.C., Lal M., Roy S.B., and Subramananyan C.S. (1969). Acute mountain sickness. N. Eng. J. Med. 280:175-184.
21. Swenson E.R. (1998). Carbonic anhydrase inhibitors and ventilation: A complex interplay of stimulation and suppression. Eur. Respir. J. 12:1242-1247.
22. Thompson W.T. (1958). The treatment of respiratory acidosis with a potent carbonic anhydrase inhibitor (dichlorphenamide). Am. J. Med. Sci. 236:603-609.
23. Travis D.M. (1969). Renal carbonic anydrase inhibition by benzolamide in man. J. Pharm. Exp. Ther. 167:253-263.
24. Ward M.P., Milledge J.S., and West J.B. (1998). In: High Altitude Medicine and Physiology. University of Pennsylvania Press, Philadelphia, pp. 377-378.
25. Wright A.D., Winterbourne H., and Bradwell A.R. (1994). Carbonic anhydrase inhibition in the immediate therapy of acute mountain sickness. J. Wild. Med. 5:49-55.
26. Zell S.C., and Goodman P.H. (1988). Acetazolamide and dexamethasone in the prevention of acute mountain sickness. West. J. Med. 148:541-545.